Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/66
A61K-031/70
출원번호
US-0321766
(1999-05-28)
등록번호
US-8415329
(2013-04-09)
발명자
/ 주소
Mishra, Awadhesh K.
출원인 / 주소
Jagotec AG
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
151
초록▼
Compositions of submicron- to micron-sized particles of water-insoluble biologically active substances that are stabilized by thermoprotecting agents, can be terminally steam sterilized without any significant increase of mean particle size. These compositions display markedly reduced heat-induced c
Compositions of submicron- to micron-sized particles of water-insoluble biologically active substances that are stabilized by thermoprotecting agents, can be terminally steam sterilized without any significant increase of mean particle size. These compositions display markedly reduced heat-induced coagulation, flocculation, or particle size growth during the terminal steam sterilization process.
대표청구항▼
1. An injectable aqueous terminally steam sterilized composition consisting essentially of a particulate suspension of a water insoluble or poorly soluble biologically active substance wherein the particles in the suspension have a volume weighted mean particle size of up to 3 μm, with not more than
1. An injectable aqueous terminally steam sterilized composition consisting essentially of a particulate suspension of a water insoluble or poorly soluble biologically active substance wherein the particles in the suspension have a volume weighted mean particle size of up to 3 μm, with not more than 3000 particles of a size of 10 μm or greater and not more than 300 particles of a size of 25 μm or greater, andsaid particles are surface stabilized with one or more phospholipid surface modifiers and a pharmaceutically acceptable amount of a water soluble polyhydroxy thermoprotecting agent selected from the group consisting of trehalose, lactose, dextrose, sorbitol, dextran, mannitol and mixtures thereof, wherein said thermoprotecting agent is present in an amount effective to restrict an increase in volume weighted mean diameter of said suspension during and after terminal steam sterilization,wherein the ratio of said active substance to said phospholipid surface modifier is from about 3:1 to about 5:1 and the amount of said phospholipid surface modifier is in the range from about 0.2% w/w to about 5.0% w/w,wherein said composition is devoid of surfactants that require during terminal steam sterilization elevation of their cloud point temperature by addition of a cloud point modifier,said composition being devoid of surfactant additives which coagulate on steam sterilization. 2. An injectable aqueous terminally steam sterilized composition consisting essentially of a particulate suspension of a water insoluble or poorly soluble biologically active substance wherein the particles in the suspension have a volume weighted mean particle size of up to 3 μm, andsaid particles are surface stabilized with one or more phospholipid surface modifiers, and a pharmaceutically acceptable amount of a water soluble polyhydroxy thermoprotecting agent, wherein said thermoprotecting agent is present in an amount effective to restrict an increase in volume weighted mean diameter of said suspension during and after terminal steam sterilization,wherein (i) the ratio of said drug substance to said surface modifier is about 3:1 to about 5:1,(ii) the amount of said surface modifier is in the range from about 0.2% w/w to about 5.0% w/w, and(iii) wherein said composition is devoid of surfactants that require during terminal steam sterilization elevation of their cloud point temperature by addition of a cloud point modifier and is devoid of surfactant additives which coagulate on steam sterilization. 3. The composition according to claim 1 or claim 2, wherein the suspension also includes a nonsurfactant additive to adjust osmotic pressure. 4. The composition according to claim 1 or claim 2, wherein the suspension is diluted with water for parenteral administration. 5. The composition according to claim 2, wherein the suspension further comprises a pharmaceutical excipient for ophthalmic, peroral, or transdermal administration of the water insoluble or poorly soluble drug substance. 6. The composition according to claim 1, wherein the active substance is an antifungal agent. 7. The composition according to claim 6, wherein the antifungal agent is itraconazole. 8. The composition according to claim 1, wherein the active substance is an immunosuppressive agent. 9. The composition according to claim 1, wherein the active substance is a sterol. 10. The composition according to claim 9, wherein the sterol is alfaxalone. 11. A lyophilized or spray dried powder prepared from the composition according to claim 2. 12. The composition according to claim 2, wherein the water-insoluble or poorly water soluble drug substance is suitable for either immediate release or sustained release delivery of said drug substance by parenteral administration. 13. The composition according to claim 12, wherein the parenteral administration is intramuscular, intravenous, or subcutaneous administration. 14. The composition according to claim 8, wherein the immunosuppressive agent is a cyclosporin. 15. The composition according to claim 1, wherein said composition consists of said particles of said water insoluble or poorly soluble biologically active substance,said one or more phospholipid surface modifiers, andsaid polyhydroxy thermoprotecting agent. 16. The composition according to claim 2, wherein said composition consists of said drug substance,said one or more phospholipid surface modifiers, andsaid polyhydroxy thermoprotecting agent. 17. The composition of claim 1, wherein the phospholipid surface modifier is egg phospholipid, or soy phospholipid. 18. The composition of claim 2, wherein the polydroxy thermoprotecting agent is selected from the group consisting of trehalose, lactose, dextrose, sorbitol, dextran, and mixtures thereof. 19. The composition of claim 2, wherein the phospholipid surface modifier is egg phospholipid, or soy phospholipid. 20. The aqueous suspension of claim 3, wherein the suspension lacks glycerol. 21. The aqueous suspension of claim 4, wherein the suspension lacks glycerol. 22. The composition of claim 1, wherein the composition is under nitrogen in a sealed vial. 23. The composition of claim 1, wherein the composition is under nitrogen in a sealed vial.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (151)
Glen John Baird (Macclesfield EN) James Roger (Macclesfield EN), 2,6-Diisopropylphenol as an anaesthetic agent.
Couvreur Patrick (8 ; Avenue de la Foret 1970 Wezembeek-Oppem BEX) Roland Michel (38 ; rue Tomberg 1150 Bruxelles BEX) Speiser Peter (26Wassbergerstrasse 8127 Forch CHX), Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them.
Wretlind Karl A. J. (Stockholm SEX) Ljungberg Stellan (LidingSEX) Hakansson Ivan (Stockholm SEX) Ajaxon Bengt M. (Upsala SEX), Composition for enhancing the administration of pharmacologically active agents.
Hong Chung Il ; Kim Jung Woo,KRX ; Choi Nam Hee,KRX ; Shin Hee Jong,KRX ; Yang Su Geun,KRX, Cyclosporin-containing microemulsion preconcentrate composition.
Reul Bernhard (Konigstein DEX) Petri Walter (Wiesbaden DEX), Drug formulations comprising coated, very sparingly water-soluble drugs for inhalational pharmaceutical forms, and proce.
Nagy ne Kricsfalussy Margit (Budapest HUX) Szauder ne Lauk Hedvig (Budapest HUX) Egri Jnos (Budapest HUX), Drug solutions of increased stability and without tissue-damaging effect and process for preparing same.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants.
Eickhoff W. Mark (Downingtown PA) Mueller Karl R. (Pexton PA) Engers David A. (Collegeville PA), Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids.
Eickhoff W. Mark (Downingtown PA) Mueller Karl R. (Pexton PA) Engers David A. (Collegeville PA), Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids.
Oppenheim ; Richard Charles ; Marty ; Jennifer Joy ; Speiser ; Peter, Injectable compositions, nanoparticles useful therein, and process of manufacturing same.
Fountain Michael W. (Plainsboro NJ) Weiss Steven J. (Lawrenceville NJ) Kearns John J. (Princeton NJ) Weiner Alan L. (Plainsboro NJ) Popescu Mircea C. (Plainsboro NJ), Lipid matrix carriers for use in drug delivery systems.
Papahadjopoulos Demetrios P. (78 Heathwood Williamsville NY 14221) Szoka ; Jr. Francis C. (375 Leroy Ave. Buffalo NY 14214), Method of encapsulating biologically active materials in lipid vesicles.
Papahadjopoulos Demetrios P. (78 Heathwood Williamsville NY 14221) Szoka ; Jr. Francis C. (375 Leroy Ave. Buffalo NY 14214), Method of encapsulating biologically active materials in lipid vesicles.
Mezei Michael (Halifax CAX) Nugent Fredric J. (Halifax CAX), Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV).
Wretlind ; Karl A. J. ; Ljungberg ; Stellan ; Hakansson ; Ivan ; Ajaxon ; Bengt M., Method of enhancing the administration of pharmalogically active agents.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of making nanoparticulate X-ray blood pool contrast agents using high molecular weight nonionic surfactants.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation.
Liversidge Gary G. (West Chester PA) Phillips Christopher P. (Brandamore PA) Cundy Kenneth C. (Belmont CA), Method to reduce particle size growth during lyophilization.
Baurain Roger (Wezembeek BEX) Trouet Andre B. L. (Winksele BEX), Microcrystals comprising an active substance having an affinity for phospholipids, and at least one phospholipid, proces.
Liversidge Gary G. ; Engers David A. ; Roberts Mary E. ; Ruddy Stephen B. ; Wong Sui-Ming ; Xu Shuqian, Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Szab Anna Z. (Budapest HUX) Gal Joszef (Budapest HUX) Mrmarosi Katalin (Budapest HUX) Sebestyn Gyula (Budapest HUX) Miholics Gizella (Budapest HUX) Kovcs Mrta (Budapest HUX), Pharmaceutical composition and process for the preparation thereof.
Dingle John T. (Whittlesford GB2) Gordon John L. (Cambridge GB2) Jones Geraint (Macclesfield GB2) Knight Clive G. (Huntingdon GB2) Lowe John S. (Wilmslow GB2), Pharmaceutical compositions.
List Paul H. (Marburg DEX) Schmidt Peter C. (Marburg DEX) Steffens Klaus-Jrgen (Marburg DEX) Perschbacher Harald (Bad Homburg DEX) Kraemer Hans P. (Marburg DEX) Sedlacek Hans H. (Marburg DEX), Pharmaceutical formulation and process for its preparation.
Cho Young W. (Chester NJ) Flynn Michael John (Surrey GB2), Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic ph.
Dietl Hans (Eichendorffstrasse 33 Bad Aibling DEX 8202), Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production.
Growdon John H. (Brookline MA) Wurtman Richard J. (Boston MA), Process and composition for treating disorders by administering isoxsurpine and choline.
Leclef Brigitte (Brussels BEX) Cerfontaine Patrick (Brussels BEX) Nicolas Jean-Marie (Overijse BEX) Wantier Henri (Dour BEX) Trouet Andr (Winksele Herent BEX), Process for preparing lipid microparticles.
Carli Fabio (Trieste ITX) Chiesi Paolo (Fontanini di Vigatto ITX), Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions.
Bosch H. William (Bryn Mawr PA) Marcera Donna M. (Collegeville PA) Mueller Ronald L. (Downingtown PA) Swanson Jon R. (Macungie PA) Mishra Dinesh S. (Harleysville PA), Process for preparing therapeutic compositions containing nanoparticles.
de Garavilla Lawrence ; Liversidge Elaine M. ; Liversidge Gary G., Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions.
Chagnon Mark S. (Pelham NH) Ferris John R. (Newburyport MA) Hamilton Tracy J. (Salem NH) Rudd Edwin A. (Salem NH) Carter Michelle J. (Derry NH), Solid care therapeutic compositions and methods for making same.
Lenk Robert P. (Lambertville NJ) Fountain Michael W. (Griggstown NJ) Janoff Andrew S. (Yardley PA) Popescu Mircea C. (Plainsboro NJ) Weiss Steven J. (Hightstown NJ) Ginsberg Richard S. (Monroe Townsh, Stable plurilamellar vesicles.
Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
Liversidge Gary G. (West Chester PA) Conzentino ; Jr. Philip (West Chester PA) Cundy Kenneth C. (Pottstown PA) Sarpotdar Pramod P. (Malvern PA), Surface modified NSAID nanoparticles.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Use of ionic cloud point modifiers to prevent particle aggregation during sterilization.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization.
Hollister Kenneth R. (Chester Springs PA) Ladd David (Wayne PA) McIntire Gregory L. (West Chester PA) Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA) Yuan Barbara O. (Villan, Use of purified surface modifiers to prevent particle aggregation during sterilization.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.